How a degrader is designed in its first weeks of discovery decides whether it ever reaches a development-stage candidate.
In 2026, the FDA approved the first proteolysis targeting chimera (PROTAC) therapeutic to reach patients, more than two decades after induced proximity first entered pharma’s toolbox as a concept. The approval proved the mechanism works, and the next wave of programs now has to get those earliest chemistry decisions right.
A 2026 analysis in the journal Protein & Cell found that no single E3 ligase consistently outperforms the others across targets and tissues. That finding cuts against treating E3 ligase choice as a default setting rather than a decision made deliberately for each program. The same logic is now expanding beyond the ubiquitin-proteasome system, with researchers engineering degraders that route target proteins through lysosomal and autophagy pathways as well, according to a 2026 review in Autophagy, widening the design space even more.
There are four decisions in particular that determine which programs make the transition from active molecule to developable one: how a degrader handles classical drug-likeness assumptions, how its E3 ligase and linker are chosen, how it’s designed for oral exposure, and how early its synthetic accessibility gets evaluated.
Treating those four decisions as one connected problem, rather than four separate ones, requires discovery, development, and manufacturing to work from the same set of decisions rather than passing a program across organizational lines. WuXi AppTec, a trusted contract research, development, and manufacturing organization (CRDMO) with more than 25 years of experience across 20-plus global sites, is built to bring those functions together under one integrated model. What that looks like in practice starts with the molecule itself.
Degraders Break the Old Rules for Drug-Likeness
Targeted protein degraders typically fall between roughly 500 and 1,500 daltons in molecular weight, well outside the range classical drug-likeness rules were built around, occupying what medicinal chemists call the beyond-Rule-of-5 (bRo5) space, according to a 2024 analysis in ADMET & DMPK. This means the heuristics built for smaller, more rigid inhibitors don’t reliably predict whether a degrader will behave like an oral drug.
An increase in molecular weight tends to reduce both solubility and membrane permeability, and larger molecules are more likely to trigger efflux pumps that push compounds back out of cells before they can act, the same analysis notes. Once a program moves into bRo5 territory, the property calculations discovery teams lean on for classical small molecules become a starting hypothesis rather than a reliable predictor.
Why E3 Ligase and Linker Choices Can’t Wait
E3 ligase and linker selection determine whether a degrader’s target-binding ligand and its ligase-recruiting ligand actually come together in a stable, productive three-way complex with the protein of interest, according to the Protein & Cell analysis cited above. A mismatched pairing is a plausible explanation for why some degraders bind their target without ever degrading it.
A 2025 review in the journal Targets found that mutations in an E3 ligase or its pathway components can abrogate a degrader’s activity entirely and noted that the field has historically leaned on only four ligases (CRBN, VHL, MDM2, and the IAP family) out of an estimated 600-700 available in the human body. Expanding beyond that default set, the review argues, gives programs a way to route around E3-linked resistance, whether that resistance is anticipated in advance or emerges after a program is already in the clinic.
Ligase and linker choices shape oral exposure and synthesis outcomes too, so discovery and process teams need to weigh them jointly.
Oral Exposure Starts With How the Molecule Is Built
Chameleonicity, a molecule’s ability to change shape with its environment, is a key property that helps some bRo5 compounds reach oral bioavailability. The molecule stays open and soluble in water, then folds into a more compact, permeable form inside a cell membrane, according to ADMET & DMPK’s analysis.
Across three PROTACs profiled in the analysis, the two built on the same E3 ligase (CRBN) each reached oral bioavailability above 30% in preclinical models, while the one built on a different ligase (VHL) and carrying a substantially larger, more polar, more flexible structure overall showed oral bioavailability of just 0.03% in comparable testing. The comparison doesn’t isolate E3 ligase choice as the cause, but it illustrates how differently two bRo5 degraders can behave depending on the overall molecule they’re built around.
Synthetic Accessibility Is Part of the Design
Bivalent degraders are often harder and more labor-intensive to synthesize than classical small molecules, according to a 2026 review in Chemistry – A European Journal, which surveys new methods aimed at closing that gap.
The same review points to newer synthetic techniques and automated screening as tools that let teams build and test more degrader candidates earlier, rather than discovering a synthetic dead end after a lead has already been chosen on binding data alone. Folding that manufacturability check into the same design cycle as E3 ligase and linker selection turns a biologically active degrader into one with a realistic path to scale.
The first PROTAC to reach patients took more than two decades to get there, proof that the mechanism itself works. The degraders now moving through discovery face a different test: whether drug-likeness, ligase and linker selection, oral exposure, and synthetic accessibility were weighed together early enough to make that same trip faster.
“Overall, drug discovery is shifting from a compound-centric exercise toward an outcome-oriented discipline, where success increasingly depends on the integration of scientific and development capabilities across the discovery continuum,” said Dr. Tao Guo, Senior Vice President, Research Chemistry Services, Integrated Program Management at WuXi AppTec.
FAQs
Question: Is the Rule of 5 still relevant for protein degrader design?
Answer: Only partly. Most protein degraders occupy the beyond-Rule-of-5 space, often 500 to 1,500 daltons, so classical drug-likeness cutoffs don’t reliably predict oral behavior. Teams now treat those rules as a starting hypothesis and not as a pass-or-fail test.
Question: Why does E3 ligase choice matter in protein degrader design?
Answer: Because it determines whether the target protein and the degrader form a stable three-way complex that triggers degradation. No single ligase outperforms the others across targets and tissues, and the wrong pairing is a common reason active-binding degraders still fail.
Question: Are protein degraders orally bioavailable?
Answer: Oral bioavailability varies widely across degrader programs. In the small set of PROTACs studied so far, molecules built on the same E3 ligase showed similar bioavailability, while a differently built molecule on a different ligase showed much lower bioavailability, though the ligase alone hasn’t been isolated as the cause.
Question: Why is targeted protein degradation hard to manufacture at scale?
Answer: Bivalent degrader molecules are often harder and more labor-intensive to synthesize than classical small molecules. Click chemistry, late-stage functionalization, and automated screening help teams test synthetic routes earlier, before a candidate is locked in on binding data alone.
Question: What determines whether a protein degrader becomes developable, not just active?
Answer: Developability depends on treating E3 ligase selection, linker design, oral-exposure strategy, and synthetic accessibility as one connected decision made early as opposed to four separate ones solved in sequence. The first PROTAC therapeutic reached FDA approval in 2026, decades after these design questions first surfaced.
